Onconetix, Inc. has announced a significant corporate restructuring with the approval of a one-for-ten reverse stock split of its common stock. This decision, effective at 12:01 a.m. Eastern Time on November 6, 2026, is designed to consolidate shares and potentially improve the stock's market perception.
The reverse stock split will reduce the number of outstanding shares from approximately 5.9 million to about 589,000 shares. This move comes as part of a broader strategy to enhance the company's standing in the competitive pharmaceutical preparations industry.
About Onconetix, Inc.
Onconetix, Inc. operates within the pharmaceutical preparations sector and is listed on the Nasdaq under the ticker symbol ONCO. The company, incorporated in Delaware, focuses on developing innovative oncology solutions, particularly through its Proclarix® diagnostic test for prostate cancer. This test has already received approval for sale in the European Union.
What the Filing Says
According to the recent SEC filing, the company’s Board of Directors has authorized the reverse stock split as part of its ongoing efforts to improve its market position. The filing states, "Every ten (10) shares of the Company’s issued and outstanding Common Stock will automatically be combined into one (1) issued and outstanding share of Common Stock." The company expects the reverse split to take effect on November 6, 2026.
Impact
This reverse stock split is expected to affect all stockholders uniformly, maintaining their percentage ownership in the company, except for those who would receive fractional shares. Stockholders holding shares in brokerage accounts will see their shares automatically adjusted, while those with physical stock certificates will have the option to exchange them for new ones.
What's Next
The company plans to file a Certificate of Amendment to its Charter with the Secretary of State of Delaware on November 5, 2026. Following this, the common stock will begin trading on a split-adjusted basis on the Nasdaq under the existing symbol ONCO.